文献速递临床试验与 GCP医学人工智能与信息学

一项随机、嵌入式、实用性贝叶斯临床试验:临床决策支持用于儿童毛细支气管炎高流量鼻导管管理的研究设计与统计分析计划

A randomized, embedded, pragmatic, Bayesian clinical trial examining clinical decision support for high flow nasal cannula management in children with bronchiolitis: design and statistical analysis plan.
PubMed 文献 · Trials · 2024-07-16

REspiratory SupporT for Efficient and cost-Effective Care(REST EEC)试验嵌入电子健康记录与质量改进流程,随机比较临床决策支持(CDS)引导的标准化高流量鼻导管(HFNC)撤机与常规护理对毛细支气管炎患儿HFNC持续时间的影响。试验模拟显示,假设真实风险比1.27(相当于中位持续时间减少6小时)、最多入组350例儿童,宣布优效性的概率大于0.75。

要点

  • CDS偶联的标准化HFNC撤机方案旨在缩短毛细支气管炎患儿HFNC持续时间。
  • 试验模拟:真实HR 1.27(中位持续时间减少6小时)、最多350例时,宣布优效性概率>0.75。
  • 试验嵌入电子健康记录与质量改进流程,采用贝叶斯推断判断干预是否优于常规护理。

核心结论

  • REST EEC试验假设CDS偶联的标准化HFNC撤机较常规护理缩短毛细支气管炎患儿HFNC持续时间(主要终点)。
  • REST EEC是学习型健康系统干预,将卫生系统运营与主动证据生成相结合,以优化HFNC使用及相关患者结局。

研究设计与样本

  • REST EEC为随机、嵌入式、实用性贝叶斯临床试验,采用电子健康记录(EHR)嵌入、面向质量改进(QI)的设计。
  • 数据来自EHR及其他真实世界数据源,利用现有信息学基础设施和QI数据源。
  • 试验工作流程(包括随机化和干预部署)嵌入一家大型儿童医院的EHR,使用现有供应商功能。
  • 试验模拟假设真实风险比(HR)效应量为1.27,相当于HFNC中位持续时间减少6小时,最多入组350例儿童。
  • 采用迭代计划-执行-研究-处理(PDSA)循环监测试验并对工作人员提供针对性教育。

主要发现

  • 试验模拟显示,在真实HR 1.27、最多入组350例儿童的假设下,宣布优效性(中期分析干预效应后验概率>0.99或最终分析干预效应后验概率>0.9)的概率大于0.75。
  • 试验模拟显示,宣布优效性或CDS干预显示前景(最终分析干预效应后验概率>0.8)的概率大于0.85。

关键数值与推荐

  • 主要终点为HFNC持续时间。
  • 优效性判定标准:中期分析干预效应后验概率>0.99或最终分析干预效应后验概率>0.9。
  • CDS干预显示前景的判定标准:最终分析干预效应后验概率>0.8。
  • 试验模拟假设真实HR效应量为1.27,相当于HFNC中位持续时间减少6小时。
  • 最多入组350例儿童。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High flow nasal cannula (HFNC) has been increasingly adopted in the past 2 decades as a mode of respiratory support for children hospitalized with bronchiolitis. The growing use of HFNC despite a paucity of high-quality data regarding the therapy's efficacy has led to concerns about overutilization. We developed an electronic health record (EHR) embedded, quality improvement (QI) oriented clinical trial to determine whether standardized management of HFNC weaning guided by clinical decision support (CDS) results in a reduction in the duration of HFNC compared to usual care for children with bronchiolitis. METHODS: The design and summary of the statistical analysis plan for the REspiratory SupporT for Efficient and cost-Effective Care (REST EEC; "rest easy") trial are presented. The investigators hypothesize that CDS-coupled, standardized HFNC weaning will reduce the duration of HFNC, the trial's primary endpoint, for children with bronchiolitis compared to usual care. Data supporting trial design and eventual analyses are collected from the EHR and other real world data sources using existing informatics infrastructure and QI data sources. The trial workflow, including randomization and deployment of the intervention, is embedded within the EHR of a large children's hospital using existing vendor features. Trial simulations indicate that by assuming a true hazard ratio effect size of 1.27, equivalent to a 6-h reduction in the median duration of HFNC, and enrolling a maximum of 350 children, there will be a > 0.75 probability of declaring superiority (interim analysis posterior probability of intervention effect > 0.99 or final analysis posterior probability of intervention effect > 0.9) and a > 0.85 probability of declaring superiority or the CDS intervention showing promise (final analysis posterior probability of intervention effect > 0.8). Iterative plan-do-study-act cycles are used to monitor the trial and provide targeted education to the workforce. DISCUSSION: Through incorporation of the trial into usual care workflows, relying on QI tools and resources to support trial conduct, and relying on Bayesian inference to determine whether the intervention is superior to usual care, REST EEC is a learning health system intervention that blends health system operations with active evidence generation to optimize the use of HFNC and associated patient outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT05909566. Registered on June 18, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Horvat CM, Suresh S, James N, et al. A randomized, embedded, pragmatic, Bayesian clinical trial examining clinical decision support for high flow nasal cannula management in children with bronchiolitis: design and statistical analysis plan. Trials. 2024. PMID: 39014495. doi:10.1186/s13063-024-08327-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。